Maximising benefits for cancer patients | Anticancerfund

Maximising benefits for cancer patients

We identify untapped potential. Opportunities in cancer research can easily be identified using common sense and scientific evidence, potentially leading to pragmatic solutions for patients in need. The Anticancer Fund's focus areas translate directly into the selection of individual research projects.

Maximising benefits for cancer patients

Improving survival rates

While breast cancer median survival time has risen 10-fold over the last 30 years, survival time of other cancers like pancreas, brain or lung cancer has barely shown any progression.

We want cancer patients to live longer, with an acceptable quality of life. Our priority is to make a real impact on their lifespans by identifying and pursuing the most significant steps forward. Prognosis varies widely across types of cancer, with some cancers better understood or easier to eradicate. However, higher patient counts trigger the availability of and investment in treatment options. The improvement of cancer survival rates over the last several decades has been unequal.

Maximising benefits for cancer patients icon

More patients, greater attention, more research

Our choice of research projects revolve around the specific goal of adding months or years to survival time. Although all progress is worthwhile, the Anticancer Fund maintains a critical overview of the added value of new drugs and treatments to maximise returns on investment for patients.

overall survival

Increasing cure rate

It goes without saying that our ultimate dream is to discover the cure for cancer. As scientists, we are aware of the complexity and variety of cancer and acknowledge the fact that the ‘magic bullet’ of cancer treatment is extremely unlikely to be developed. The biology of cancer malignance pushes the boundaries of our scientific understanding. In the face of cancer’s resourcefulness in defeating therapies, the feasibility of our dream remains an open question.

Controlling recurrence is the main strategy for higher cure rates. With 90% of deaths resulting from tumor recurrence and metastasis, a primary cancer that is eradicated and prevented from returning is considered cured.

Increasing cure rate

Emphasising quality of life

The potential of a treatment is not simply defined by survival rate. True patient centeredness revolves around quality of life as another key indicator of treatment efficacy, with treatment toxicity and side-effects fully considered.

Patient needs are extremely important to us. We listen carefully to the personal experiences and priorities of each individual cancer patient, as we believe that giving patients the freedom to make informed choices is to recognise their rights.

"Patient centeredness should NOT be used as a loose term. We should carefully listen to patients’ needs and add treatment options that are relevant to the personal experience and priorities of each individual. Giving patients choices is recognising their rights."
Sergio Crispino, MD, Scientific Consultant at ACF

Our current focus areas

  • Drug repurposing

    Drug repurposing, also known as drug repositioning, is a drug development strategy predicated on the reuse of existing...
  • Less common and rare cancers

    We don’t just focus on the ‘big four’ of cancer – prostate, colon, breast and lung. We also investigate new treatment...
  • Combination therapies

    It is important to investigate the impacts of drugs beyond what they can achieve alone. Using them in combination can...
  • Controlling tumour recurrence

    For cancer survivors, the fight isn’t always over. Many are concerned about the possibility of recurrence, and living...